235 related articles for article (PubMed ID: 34748673)
1. Risankizumab-induced paradoxical pustular psoriasis.
McFeely O; Pender E; Victory L; Almutlaq H; Storan E
Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
3. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
4. A drug safety evaluation of risankizumab for psoriasis.
Huang YW; Tsai TF
Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
[No Abstract] [Full Text] [Related]
5. Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L; Maloney V; Gordon KB
Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
8. Generalized pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-plantar pustulosis.
De Silva BD; Benton EC; Tidman MJ
Clin Exp Dermatol; 1999 Jan; 24(1):10-3. PubMed ID: 10233640
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab-induced paradoxical pustular psoriasis.
Dogra S; Bishnoi A; Narang T; Handa S
Clin Exp Dermatol; 2019 Jan; 44(1):72-73. PubMed ID: 30129214
[No Abstract] [Full Text] [Related]
11. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
[No Abstract] [Full Text] [Related]
12. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
McDonald J; Maliyar K; Gooderham MJ
Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
[TBL] [Abstract][Full Text] [Related]
13. Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
Paton DM
Drugs Today (Barc); 2019 Oct; 55(10):605-613. PubMed ID: 31720558
[TBL] [Abstract][Full Text] [Related]
14. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
16. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection.
Ephrem G; Jour G; Smith BL
J Med Liban; 2011; 59(3):168-9. PubMed ID: 22259908
[TBL] [Abstract][Full Text] [Related]
18. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
